메뉴 건너뛰기




Volumn 16, Issue 1, 2016, Pages 55-60

Advances in pathogenesis and treatment of systemic sclerosis

Author keywords

Fibrosis; Pulmonary hypertension and autoantibodies; Scleroderma; Systemic sclerosis

Indexed keywords

AUTOANTIBODY; IMMUNOSUPPRESSIVE AGENT;

EID: 84970923254     PISSN: 14702118     EISSN: 14734893     Source Type: Journal    
DOI: 10.7861/clinmedicine.16-1-55     Document Type: Article
Times cited : (41)

References (37)
  • 1
    • 77950261786 scopus 로고    scopus 로고
    • Improved survival in systemic sclerosis is associated with better ascertainment of internal organ disease: A retrospective cohort study
    • Nihtyanova SI, Tang EC, Coghlan JG et al. Improved survival in systemic sclerosis is associated with better ascertainment of internal organ disease: a retrospective cohort study. QJM 2010; 103: 109-15.
    • (2010) QJM , vol.103 , pp. 109-115
    • Nihtyanova, S.I.1    Tang, E.C.2    Coghlan, J.G.3
  • 2
    • 84655175061 scopus 로고    scopus 로고
    • Understanding fibrosis in systemic sclerosis: Shifting paradigms, emerging opportunities
    • Bhattacharyya S, Wei J, Varga J. Understanding fibrosis in systemic sclerosis: shifting paradigms, emerging opportunities. Nat Rev Rheumatol 2011; 8: 42-54.
    • (2011) Nat Rev Rheumatol , vol.8 , pp. 42-54
    • Bhattacharyya, S.1    Wei, J.2    Varga, J.3
  • 3
    • 84862765265 scopus 로고    scopus 로고
    • Unraveling the genetic component of systemic sclerosis
    • Martín JE, Bossini-Castillo L, Martín J. Unraveling the genetic component of systemic sclerosis. Hum Genet 2012; 131: 1023-37.
    • (2012) Hum Genet , vol.131 , pp. 1023-1037
    • Martín, J.E.1    Bossini-Castillo, L.2    Martín, J.3
  • 4
    • 34548843398 scopus 로고    scopus 로고
    • A polymorphism in the CTGF promoter region associated with systemic sclerosis
    • Fonseca C, Lindahl GE, Ponticos M et al. A polymorphism in the CTGF promoter region associated with systemic sclerosis. N Engl J Med 2007; 357: 1210-20.
    • (2007) N Engl J Med , vol.357 , pp. 1210-1220
    • Fonseca, C.1    Lindahl, G.E.2    Ponticos, M.3
  • 5
    • 84879298794 scopus 로고    scopus 로고
    • Scleroderma pathogenesis: A pivotal role for fibroblasts as effector cells
    • Gilbane AJ, Denton CP, Holmes AM. Scleroderma pathogenesis: a pivotal role for fibroblasts as effector cells. Arthritis Res Ther 2013; 15: 215.
    • (2013) Arthritis Res Ther , vol.15 , pp. 215
    • Gilbane, A.J.1    Denton, C.P.2    Holmes, A.M.3
  • 6
    • 84897517521 scopus 로고    scopus 로고
    • Association of anti-RNA polymerase III autoantibodies and cancer in scleroderma
    • Moinzadeh P, Fonseca C, Hellmich M et al. Association of anti-RNA polymerase III autoantibodies and cancer in scleroderma. Arthritis Res Ther 2014; 16: R53.
    • (2014) Arthritis Res Ther , vol.16 , pp. R53
    • Moinzadeh, P.1    Fonseca, C.2    Hellmich, M.3
  • 7
    • 84922822961 scopus 로고    scopus 로고
    • Review: Cancer-induced autoimmunity in the rheumatic diseases
    • Shah AA, Casciola-Rosen L, Rosen A. Review: cancer-induced autoimmunity in the rheumatic diseases. Arthritis Rheumatol 2015; 67: 317-26.
    • (2015) Arthritis Rheumatol , vol.67 , pp. 317-326
    • Shah, A.A.1    Casciola-Rosen, L.2    Rosen, A.3
  • 8
    • 84898775777 scopus 로고    scopus 로고
    • Prediction of pulmonary complications and long-term survival in systemic sclerosis
    • Nihtyanova SI, Schreiber BE, Ong VH et al. Prediction of pulmonary complications and long-term survival in systemic sclerosis. Arthritis Rheumatol 2014; 66: 1625-35.
    • (2014) Arthritis Rheumatol , vol.66 , pp. 1625-1635
    • Nihtyanova, S.I.1    Schreiber, B.E.2    Ong, V.H.3
  • 9
    • 84886801549 scopus 로고    scopus 로고
    • Endothelial injury in a transforming growth factor-dependent mouse model of scleroderma induces pulmonary arterial hypertension
    • Derrett-Smith EC, Dooley A et al. Endothelial injury in a transforming growth factor-dependent mouse model of scleroderma induces pulmonary arterial hypertension. Arthritis Rheum 2013; 65: 2928-39.
    • (2013) Arthritis Rheum , vol.65 , pp. 2928-2939
    • Derrett-Smith, E.C.1    Dooley, A.2
  • 10
    • 84863812038 scopus 로고    scopus 로고
    • Fra-2 transgenic mice as a novel model of pulmonary hypertension associated with systemic sclerosis
    • Maurer B, Reich N, Juengel A e t al. Fra-2 transgenic mice as a novel model of pulmonary hypertension associated with systemic sclerosis . Ann Rheum Dis 2012; 71: 1382-7.
    • (2012) Ann Rheum Dis , vol.71 , pp. 1382-1387
    • Maurer, B.1    Reich, N.2    Juengel, A.3
  • 11
    • 84924758403 scopus 로고    scopus 로고
    • Impaired BMPRII signalling in a TGF dependent mouse model of pulmonary hypertension and in systemic sclerosis
    • Gilbane AJ, Derrett-Smith E, Trinder SL et al. Impaired BMPRII signalling in a TGF dependent mouse model of pulmonary hypertension and in systemic sclerosis. Am J Respir Crit Care Med 2015; 191: 665-77.
    • (2015) Am J Respir Crit Care Med , vol.191 , pp. 665-677
    • Gilbane, A.J.1    Derrett-Smith, E.2    Trinder, S.L.3
  • 12
    • 84886777196 scopus 로고    scopus 로고
    • 2013 classification criteria for systemic sclerosis: An American College of Rheumatology/European League against Rheumatism collaborative initiative
    • van den Hoogen F, Khanna D, Fransen J et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum 2013; 65: 2737-47.
    • (2013) Arthritis Rheum , vol.65 , pp. 2737-2747
    • Van Den Hoogen, F.1    Khanna, D.2    Fransen, J.3
  • 13
    • 0018887574 scopus 로고
    • Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee
    • Preliminary criteria for the classification of systemic sclerosis (scleroderma)
    • Preliminary criteria for the classification of systemic sclerosis (scleroderma) . Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980; 23: 581-90.
    • (1980) Arthritis Rheum , vol.23 , pp. 581-590
  • 14
    • 76649085510 scopus 로고    scopus 로고
    • Autoantibodies as predictive tools in systemic sclerosis
    • Nihtyanova SI, Denton CP. Autoantibodies as predictive tools in systemic sclerosis. Nat Rev Rheumatol 2010; 6: 112-6.
    • (2010) Nat Rev Rheumatol , vol.6 , pp. 112-116
    • Nihtyanova, S.I.1    Denton, C.P.2
  • 15
    • 80051468836 scopus 로고    scopus 로고
    • Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): An open-label, randomised phase 2 trial
    • Burt RK, Shah SJ, Dill K et al. Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial. Lancet 2011; 378: 498-506.
    • (2011) Lancet , vol.378 , pp. 498-506
    • Burt, R.K.1    Shah, S.J.2    Dill, K.3
  • 16
    • 84902844800 scopus 로고    scopus 로고
    • Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: A randomized clinical trial
    • van Laar JM, Farge D, Sont JK et al.; EBMT/EULAR Scleroderma Study Group. Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. JAMA 2014; 311: 2490-8.
    • (2014) JAMA , vol.311 , pp. 2490-2498
    • Van Laar, J.M.1    Farge, D.2    Sont, J.K.3
  • 17
    • 34948847074 scopus 로고    scopus 로고
    • Adult stem cell treatment of scleroderma
    • Tyndall A, Furst DE. Adult stem cell treatment of scleroderma. Curr Opin Rheumatol 2007; 19: 604-10.
    • (2007) Curr Opin Rheumatol , vol.19 , pp. 604-610
    • Tyndall, A.1    Furst, D.E.2
  • 18
    • 73649119523 scopus 로고    scopus 로고
    • Observational study of treatment outcome in early diffuse cutaneous systemic sclerosis
    • H errick A L, L unt M, W hidby N e t al. Observational study of treatment outcome in early diffuse cutaneous systemic sclerosis. J Rheumatol 2010; 37: 1162-4.
    • (2010) J Rheumatol , vol.37 , pp. 1162-1164
    • Errick A L, H.1    Unt M, L.2    Hidby N, W.3
  • 19
    • 84970921186 scopus 로고    scopus 로고
    • Available online at[Accessed 28 October 2015]
    • E uropean Scleroderma Observational Study. Available online at: www.ssc-esos.net [Accessed 28 October 2015].
    • European Scleroderma Observational Study1
  • 20
    • 66149100618 scopus 로고    scopus 로고
    • EULAR recommendations for the treatment of systemic sclerosis: A report from the EULAR Scleroderma Trials and Research group (EUSTAR)
    • Kowal-Bielecka O, Landewé R, Avouac J et al; EUSTAR Co-Authors. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis 2009; 68: 620-8.
    • (2009) Ann Rheum Dis , vol.68 , pp. 620-628
    • Kowal-Bielecka, O.1    Landewé, R.2    Avouac, J.3
  • 21
    • 84946741528 scopus 로고    scopus 로고
    • Consensus best practice pathway of the UK Systemic Sclerosis Study Group: Digital vasculopathy in systemic sclerosis
    • press
    • Hughes M, Ong VH, Anderson ME e t al. Consensus best practice pathway of the UK Systemic Sclerosis Study Group: Digital vasculopathy in systemic sclerosis. Rheumatology 2015, in press.
    • (2015) Rheumatology
    • Hughes, M.1    Ong, V.H.2    Anderson, M.E.3
  • 22
    • 33745227399 scopus 로고    scopus 로고
    • Cyclophosphamide versus placebo in scleroderma lung disease
    • Tashkin DP, Elashoff R, Clements PJ et al. Scleroderma Lung Study Research Group. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006; 354: 2655-66.
    • (2006) N Engl J Med , vol.354 , pp. 2655-2666
    • Tashkin, D.P.1    Elashoff, R.2    Clements, P.J.3
  • 23
    • 36249001195 scopus 로고    scopus 로고
    • Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease
    • T ashkin D P, E lashoff R, C lements P J e t al; Scleroderma Lung Study Research Group. Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am J Respir Crit Care Med 2007; 176: 1026-34.
    • (2007) Am J Respir Crit Care Med , vol.176 , pp. 1026-1034
    • Ashkin D P, T.1    Lashoff R, E.2    Lements P J, C.3
  • 24
    • 33845643063 scopus 로고    scopus 로고
    • A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma
    • Hoyles RK, Ellis RW, Wellsbury J et al. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum 2006; 54: 3962-70.
    • (2006) Arthritis Rheum , vol.54 , pp. 3962-3970
    • Hoyles, R.K.1    Ellis, R.W.2    Wellsbury, J.3
  • 25
    • 84890776626 scopus 로고    scopus 로고
    • Definitions and diagnosis of pulmonary hypertension
    • Hoeper MM, Bogaard HJ, Condliffe R et al. Definitions and diagnosis of pulmonary hypertension. J Am Coll Cardiol 2013; 62 ( 25 Suppl): D42-50.
    • (2013) J Am Coll Cardiol , vol.62 , Issue.25 , pp. D42-50
    • Hoeper, M.M.1    Bogaard, H.J.2    Condliffe, R.3
  • 26
    • 84931568718 scopus 로고    scopus 로고
    • Effects of oral treatments on clinical outcomes in pulmonary arterial hypertension: A systematic review and meta-analysis
    • e14
    • Zhang HD, Zhang R, Jiang X et al. Effects of oral treatments on clinical outcomes in pulmonary arterial hypertension: A systematic review and meta-analysis. Am Heart J 2015; 170: 96-103. e14.
    • (2015) Am Heart J , vol.170 , pp. 96-103
    • Zhang, H.D.1    Zhang, R.2    Jiang, X.3
  • 27
    • 84890574392 scopus 로고    scopus 로고
    • Updated treatment algorithm of pulmonary arterial hypertension
    • Galiè N, Corris PA, Frost A et al. Updated treatment algorithm of pulmonary arterial hypertension. J Am Coll Cardiol 2013; 62 ( 25 Suppl): D60-72.
    • (2013) J Am Coll Cardiol , vol.62 , Issue.25 , pp. D60-72
    • Galiè, N.1    Corris, P.A.2    Frost, A.3
  • 28
    • 0025152770 scopus 로고
    • Outcome of renal crisis in systemic sclerosis: Relation to availability of angiotensin converting enzyme (ACE) inhibitors
    • Steen VD, Costantino Shapiro JP Medsger AP Jr TA. Outcome of renal crisis in systemic sclerosis: relation to availability of angiotensin converting enzyme (ACE) inhibitors. Ann Intern Med 1990; 113: 352-7.
    • (1990) Ann Intern Med , vol.113 , pp. 352-357
    • Steen, V.D.1    Costantino Shapiro, J.P.2    Medsger, A.P.T.A.3
  • 29
    • 34547822481 scopus 로고    scopus 로고
    • Scleroderma renal crisis: Patient characteristics and long-term outcomes
    • Penn H, Howie AJ, Kingdon EJ et al. Scleroderma renal crisis: patient characteristics and long-term outcomes. QJM 2007; 100: 485-94.
    • (2007) QJM , vol.100 , pp. 485-494
    • Penn, H.1    Howie, A.J.2    Kingdon, E.J.3
  • 31
    • 77955729148 scopus 로고    scopus 로고
    • Assessment of gastrointestinal symptoms in patients with systemic sclerosis in a UK tertiary referral centre
    • Thoua NM, Bunce C, Brough G et al. Assessment of gastrointestinal symptoms in patients with systemic sclerosis in a UK tertiary referral centre. Rheumatology (Oxford) 2010; 49: 1770-5.
    • (2010) Rheumatology (Oxford) , vol.49 , pp. 1770-1775
    • Thoua, N.M.1    Bunce, C.2    Brough, G.3
  • 32
    • 85006320635 scopus 로고    scopus 로고
    • Prevalence and predictors of small intestinal bacterial overgrowth in systemic sclerosis patients with gastrointestinal symptoms
    • Tauber M, Avouac J, Benahmed A e t al. Prevalence and predictors of small intestinal bacterial overgrowth in systemic sclerosis patients with gastrointestinal symptoms. Clin Exp Rheumatol 2014; 32( 6 Suppl 86): S-82-7.
    • (2014) Clin Exp Rheumatol , vol.32 , Issue.6 , pp. S82-S87
    • Tauber, M.1    Avouac, J.2    Benahmed, A.3
  • 33
    • 84938958673 scopus 로고    scopus 로고
    • C onsensus best practice pathway of the UK scleroderma study group: Gastrointestinal manifestations of systemic sclerosis
    • Hansi N, Thoua N, Carulli M e t al. C onsensus best practice pathway of the UK scleroderma study group: gastrointestinal manifestations of systemic sclerosis. Clin Exp Rheumatol 2014; 32( 6 Suppl 86): S-214-21.
    • (2014) Clin Exp Rheumatol , vol.32 , Issue.6 , pp. S214-S221
    • Hansi, N.1    Thoua, N.2    Carulli, M.3
  • 34
    • 84908268041 scopus 로고    scopus 로고
    • Impaired quality of life in patients with systemic sclerosis compared to the general population and chronic dermatoses
    • Bretterklieber A, Painsi C, Avian A, Wutte N, Aberer E. Impaired quality of life in patients with systemic sclerosis compared to the general population and chronic dermatoses. BMC Res Notes 2014; 7: 594.
    • (2014) BMC Res Notes , vol.7 , pp. 594
    • Bretterklieber, A.1    Painsi, C.2    Avian, A.3    Wutte, N.4    Aberer, E.5
  • 35
    • 84902249499 scopus 로고    scopus 로고
    • Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: The DETECT study
    • Coghlan JG, Denton CP, Grünig E et al.; DETECT study group. Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study. Ann Rheum Dis 2014; 73: 1340-9.
    • (2014) Ann Rheum Dis , vol.73 , pp. 1340-1349
    • Coghlan, J.G.1    Denton, C.P.2    Grünig, E.3
  • 36
    • 80052339811 scopus 로고    scopus 로고
    • Prediction of pulmonary hypertension related to systemic sclerosis by an index based on simple clinical observations
    • Meune C, Avouac J, Airò P et al. Prediction of pulmonary hypertension related to systemic sclerosis by an index based on simple clinical observations. Arthritis Rheum 2011; 63: 2790-6.
    • (2011) Arthritis Rheum , vol.63 , pp. 2790-2796
    • Meune, C.1    Avouac, J.2    Airò, P.3
  • 37
    • 84901599531 scopus 로고    scopus 로고
    • Derivation and validation of a prediction rule for two-year mortality in early diffuse cutaneous systemic sclerosis
    • Domsic RT, Nihtyanova SI, Wisniewski SR et al. Derivation and validation of a prediction rule for two-year mortality in early diffuse cutaneous systemic sclerosis. Arthritis Rheumatol 2014; 66: 1616-24.
    • (2014) Arthritis Rheumatol , vol.66 , pp. 1616-1624
    • Domsic, R.T.1    Nihtyanova, S.I.2    Wisniewski, S.R.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.